FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

Melanotan I

Afamelanotide / Scenesse / MT-1 / NDP-alpha-MSH

Beauty & Skincare

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

Meccanismo d'azione

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Research protocols use 0.5-1mg daily via subcutaneous injection for 10-14 days as a loading phase, then 0.5mg 2-3 times weekly for maintenance. Some UV exposure enhances tanning response.

Note di ricerca

Clinical Research Status

Afamelanotide received FDA approval in October 2019 and EMA approval in 2014 for erythropoietic protoporphyria, making it one of the few melanocortin peptides to achieve regulatory approval. Additional clinical trials have investigated its potential in vitiligo (to enhance repigmentation when combined with UV therapy), polymorphous light eruption, and solar urticaria. Research into its photoprotective properties for skin cancer prevention in organ transplant recipients has also been explored in Phase II studies.

Key Published Findings

The pivotal Phase III trial (CUV039) demonstrated that afamelanotide significantly increased pain-free time in sunlight for EPP patients compared to placebo, with a median increase of approximately 70 hours over a 6-month period. Vitiligo studies show enhanced and accelerated repigmentation when afamelanotide implants are combined with narrowband UVB phototherapy compared to phototherapy alone. Mechanistic research confirms that MC1R activation by afamelanotide triggers eumelanin synthesis through the cAMP/PKA pathway without requiring UV exposure.

Safety Profile

The most common adverse effects include nausea, headache, and darkening of pre-existing nevi (moles), with injection site reactions at the implant location. Unlike Melanotan II, afamelanotide does not typically cause facial flushing, nausea at therapeutic doses, or sexual side effects due to its selectivity for MC1R over MC3R/MC4R. Long-term surveillance data spanning over a decade of use has not identified increased melanoma risk, though regular dermatological monitoring is recommended.

Comparison to Related Compounds

Melanotan I is a linear peptide with high MC1R selectivity, while Melanotan II is a cyclic heptapeptide with broad activity across MC1R, MC3R, MC4R, and MC5R receptors, explaining MT-II's wider side effect profile including appetite suppression and sexual effects. Afamelanotide produces more gradual, natural-appearing tanning compared to the rapid but sometimes uneven pigmentation seen with Melanotan II. The FDA-approved implant formulation provides sustained release over approximately 60 days, whereas MT-II requires frequent subcutaneous injections.

Community Observations

Users seeking cosmetic tanning generally prefer Melanotan II for its faster onset and additional effects, while those specifically interested in photoprotection without sexual side effects may prefer Melanotan I. The FDA-approved implant form (Scenesse) is extremely expensive and limited to EPP patients, leading some users to source research-grade afamelanotide powder for self-administration. Community reports suggest more natural and even tanning compared to MT-II, but with a slower onset typically requiring 2-4 weeks before visible pigmentation changes.

Semplifichro

~30 minutes

Riconcimimento

Bacteriostatic water (BAC)

Conservazione

Lyofilizzato

Refrigerate 2-8C up to 24 months. Protect from light.

Riconcimato

Refrigerate 2-8C. Use within 30 days.

Stato legale USA

FDA-approved for EPP only (Rx - Scenesse)

Anche noto come

AfamelanotideScenesseMT-1NDP-alpha-MSH

Domande frequenti

Che cos'è Melanotan I?

Melanotan I (afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte stimulating hormone (alpha-MSH) that selectively agonizes the melanocortin-1 receptor (MC1R) to stimulate eumelanin production in the skin. It is FDA-approved under the brand name Scenesse as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike its counterpart Melanotan II, afamelanotide has a more selective receptor profile with significantly fewer systemic side effects.

Come agisce Melanotan I?

Synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). Binds melanocortin-1 receptor (MC1R) on melanocytes, stimulating eumelanin production and distribution. Produces gradual, UV-independent tanning. Does not significantly affect sexual function (unlike MT-II).

Qual è lo stato normativo di Melanotan I negli Stati Uniti?

FDA-approved for EPP only (Rx - Scenesse)

Qual è l'emivita di Melanotan I?

~30 minutes

Con quali altri nomi è noto Melanotan I?

Afamelanotide, Scenesse, MT-1, NDP-alpha-MSH

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità